Seladelpar
As of the edition of 20 October 2026, Seladelpar is a small molecule: marketed, first approved in 2024 (US); acts on PPARD; US protection ends in 2031.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Small molecule
- Brand name
- Livdelzi
- First approved
- 14 August 2024 (US)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Gilead Sciences; 2 holders in all
- Registered trials
- 14, 3 stopped early
- Disease areas
- Digestive system; Nutrition and metabolism; Inherited and neonatal
US protection
US protection ends in 2031.
The last listed US exclusivity ends in 2031. The application that gives this date is held by Gilead Sciences.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product4 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 4 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Seladelpar.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PPARD | Peroxisome proliferator-activated receptor delta | Q03181 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 7 | 3 | 1 | 3 |
| Phase 3 | 5 | 3 | 2 | 0 |
| All trials | 14 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Gilead Sciences | Applicant, Acquired holder and Lead sponsor of trials | 2007 to now |